Diagnostic anti-[Human papilloma virus (HPV)] antibodies pairs for testing in ELISA, Lateral flow immunoassay (LFIA) and other immunoassays

Cat No.: GMP-HPV-1Ab

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. The relationship of cervical cancer and sexual behavior was suspected for more than 100 years and was established by epidemiologic studies in the 1960s. In the early 1980s, cervical cancer cells were demonstrated to contain HPV DNA. Epidemiologic studies showing a consistent association between HPV and cervical cancer were published in the 1990s. The first vaccine to prevent infection with four types of HPV was licensed in 2006.Genemedi produces core diagnostic ingredients-validated antibodies pairs Mouse anti-Human papilloma virus (HPV) monoclonal antibody for rapid test kit of Human papilloma virus (HPV) to evaluate the related human infectious disease.The paired antibodies are both monoclonal antibody(mab).

All the antibodies and antiges of animal disease test are suitable for in functional ELISA, and other immunoassays in diagnostics.The antibody can act as a capture antibody and detection antibody. Antigens are validated as positive control materials.

Order information

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-HPV-1Ab-1mg 1mg 1953
GMP-HPV-1Ab-10mg 10mg 13671
GMP-HPV-1Ab-100mg 100mg 95697
GMP-HPV-1Ab-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Antigen & Antibody Name Mouse anti-Human papilloma virus (HPV) monoclonal antibody
Expression platform CHO
IsotypesMouse IgG
Bioactivity validationAntibody Binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays in[Human papilloma virus (HPV)] level test in human infectious disease diagnositcs.
TagmFc
Products descriptionHuman papillomavirus (HPV) is the most common sexually transmitted infection in the United States. The relationship of cervical cancer and sexual behavior was suspected for more than 100 years and was established by epidemiologic studies in the 1960s. In the early 1980s, cervical cancer cells were demonstrated to contain HPV DNA. Epidemiologic studies showing a consistent association between HPV and cervical cancer were published in the 1990s. The first vaccine to prevent infection with four types of HPV was licensed in 2006.
PurityPurity: ≥95% (SDS-PAGE)
Application ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.